16-OH-E1 Test

Estrogen is not just one thing your body makes and uses. It is made, then broken down through different chemical routes, and the route your body favors matters. 16-OH-E1 (16-alpha-hydroxyestrone) is one of those breakdown products, and it is the one researchers worry about most because it acts powerfully on tissue and can damage DNA.

Measuring 16-OH-E1 in urine gives you a window into how your body is processing estrogen. It will not tell you whether you have cancer or a hormone disorder, but it can help you see whether your estrogen metabolism is leaning toward a more harmful pattern, particularly when paired with its sister metabolite 2-OH-E1 as a ratio.

What This Metabolite Actually Is

Your body makes estrogen, uses it, then breaks it down. The two main breakdown routes are 2-hydroxylation and 16-hydroxylation. The 2-pathway produces weaker, generally less reactive products. The 16-pathway produces 16-OH-E1, a strongly estrogenic metabolite that binds tightly to estrogen receptors and has been shown to damage DNA. Liver enzymes from the cytochrome P450 family (a group of liver enzymes that break down hormones and drugs) handle both routes, and your individual mix of genetics, body composition, and exposures shifts the balance between them.

Because the two pathways compete, researchers often look at the 2-OH-E1 to 16-OH-E1 ratio rather than 16-OH-E1 alone. A higher ratio means more estrogen is being routed through the weaker pathway. A lower ratio means more is being pushed through the stronger, more reactive 16-pathway.

Breast Cancer Risk

This is where 16-OH-E1 has been studied most, with mixed results. A prospective study of premenopausal women found that a higher 2-OH-E1 to 16-OH-E1 ratio was linked to a reduced risk of invasive breast cancer. In postmenopausal women, evidence is inconsistent: some case-control studies have linked a lower ratio to higher risk, while others, including studies in 142 postmenopausal women and 563 older women, found no meaningful association between the ratio and breast cancer.

A more recent long-term follow-up of 1,361 women with breast cancer found that urinary estrogen metabolite levels were inversely associated with all-cause mortality, suggesting the relationship between these metabolites and outcomes is more nuanced than a simple bad-number framing.

How to think about this: 16-OH-E1 is not a yes-or-no cancer test, and a single reading should not drive a cancer decision. The strongest signal comes from the ratio with 2-OH-E1, and even that is best used as one input among many for women thinking about their long-term estrogen exposure.

Obesity and Metabolic Health

Body fat changes how your body handles estrogen. In a study of 135 premenopausal women, urinary 16-OH-E1 rose with body weight and correlated with higher LDL cholesterol, higher insulin, higher triglycerides, and lower HDL. In 35 obese prepubertal girls, serum 16-OH-E1 was markedly higher than in lean peers and correlated with body mass index, fat mass, and the inflammatory marker interleukin-6.

The pattern is consistent: more body fat tends to push estrogen metabolism toward the 16-pathway. This is one reason 16-OH-E1 is sometimes treated as a metabolic marker, not just a hormone marker.

Gestational Diabetes and Pregnancy

A study of 110 pregnant women found that 16-OH-E1 was markedly elevated in women with gestational diabetes compared to healthy controls, with women in the highest quartile of 16-OH-E1 showing strongly increased odds of developing the condition. A separate study of 24 women with preeclampsia found higher 16-OH-E1 in mild cases. These findings are not yet a basis for routine pregnancy screening, but they point to a real connection between this metabolite and pregnancy-related metabolic stress.

Endometrial and Vascular Effects

In a study of 200 premenopausal women, those with overweight and endometrial hyperplasia with atypia (an abnormal thickening of the uterine lining that can precede cancer) had elevated urinary 16-OH-E1. Separately, laboratory work on human pulmonary artery cells showed that 16-OH-E1 drives oxidative stress (cell damage from unstable molecules) and cell growth signals relevant to pulmonary arterial hypertension, a serious disease of the lung blood vessels. The cell-based work is mechanistic rather than clinical, but it helps explain why this metabolite is treated as biologically active rather than inert.

Reconciling the Mixed Evidence

If you have read this far you have seen findings that point in different directions: 16-OH-E1 looks harmful in some studies and neutral in others, and the same is true for the 2-OH-E1 to 16-OH-E1 ratio. The framework that makes both findings consistent is this: 16-OH-E1 is not a clean good-or-bad number. It is a pattern indicator. The same metabolite that promotes proliferation in breast tissue may behave differently in postmenopausal women with lower overall estrogen production, or in women whose risk is dominated by other factors entirely. Treating 16-OH-E1 as one piece of a profile, not a verdict, matches the evidence.

Reference Ranges

There are no universally accepted clinical cutpoints for 16-OH-E1. It is a research-stage marker, and reported values depend heavily on the assay used, the specimen (urine vs serum), and the population studied. The numbers below come from a randomized trial in postmenopausal Danish women using an enzyme immunoassay on urine. They are illustrative orientation, not a target. Your lab will likely report different numbers, possibly in different units.

Compare your results within the same lab over time for the most meaningful trend. Mass-spectrometry assays produce more accurate values than older immunoassays, especially at the lower concentrations typical of postmenopausal women, so switching labs or methods can shift your number even when nothing has changed in your body.

Tracking Your Trend

A single 16-OH-E1 reading is almost never enough. Estrogen metabolism shifts with menstrual cycle phase, body weight, oral contraceptive use, certain supplements, and diet. The question worth answering is not where you are on a single day. It is whether your trend is moving in a more favorable direction over time, particularly your 2-OH-E1 to 16-OH-E1 ratio.

A reasonable cadence: get a baseline, retest in 3 to 6 months if you are making meaningful changes (diet, weight, supplements), and then at least annually. Premenopausal women should aim to collect samples at a consistent point in the menstrual cycle (often the luteal phase) to make readings comparable.

What to Do If Your Result Looks Unfavorable

If your 16-OH-E1 is high or your 2-OH-E1 to 16-OH-E1 ratio is low, the next step is not a single intervention. It is to put the result in context. Look at companion markers: total urinary estrogens, the 4-hydroxylation pathway metabolites, and methylation markers that show how well your body is neutralizing reactive estrogens. If you are dealing with strong family history of breast or endometrial cancer, persistent obesity, or pregnancy complications, the result is worth discussing with a clinician who works with hormone metabolism (a gynecologist, endocrinologist, or trained functional medicine physician). A pattern of low 2-OH-E1, high 16-OH-E1, and high 4-OH-E1 is more informative than any single value.

When Results Can Be Misleading

Several things can shift a single reading without reflecting your underlying biology:

• Menstrual cycle phase: estrogen metabolism varies across the cycle. A premenopausal sample collected at random will be harder to interpret than one collected at a defined point.
• Oral contraceptive use: combined oral contraceptives containing ethinyl estradiol and drospirenone have been shown to lower 16-OH-E1 and several other 16-pathway metabolites. The shift is real but reflects the drug, not your underlying tendency.
• Assay differences: enzyme immunoassays and mass-spectrometry methods can produce different absolute values for the same sample, especially when concentrations are low.
• Supplements taken before testing: diindolylmethane (DIM) and indole-3-carbinol shift the ratio within weeks of starting, so a recent supplement change can alter the reading.